Pharma Solutions are one of the very few CDMO’s that have a bespoke, fully
equipped non-GMP pilot plant designed to reduce the timelines and the costs for
scale up and transfer of spray drying processes into GMP.
Spray Drying Development and Scale up=
Formulation and early process
development studies are performed in the Upperton spray drying development
suite on one of our laboratory-scale Büchi B290 spray dryers.
These are excellent spray dryers for early development studies; enabling us to
produce stable formulations to meet our customers' requirements. They also
allow us to define the process design space for producing the spray dried
formulation using a DoE approach.
The next step towards clinical manufacture is transfer of the process onto one of the GMP-compliant spray dryers, housed in our non-GMP pilot plant.
Depending upon the scale eventually required for clinical manufacture, the
process may be transferred onto our ProCepT 4M8-TriX spray dryer or it may be
scaled up onto our GEA Niro Mobile Minor spray dryer which can be used to produce
batches of up to ~3kg spray dried product.
The Upperton pilot plant is equipped with exactly the same spray dryers as our
GMP facility. This allows us to produce kilogram quantities of non-GMP material
to support toxicology and stability studies at a fraction of the cost of GMP
Once tech transfer / scale up studies are completed: A Master Batch Record
can be produced, Chemistry, Manufacturing and Controls (CMC) batches can be
manufactured and the process is ready to be transferred directly into the GMP
facility for clinical manufacture.
Engineered Powders for Enhanced Pulmonary Delivery
Upperton is continuing to invest in its combined spray
drying and micronisation technology in order to meet
increased demand. This emerging processing technology has been developed to
enable the production of larger quantities of dry powder formulations suitable
for pulmonary delivery.
The expansion of this service has been driven by growing
demand for this exciting next generation pulmonary delivery technology
particularly from customers requiring GMP manufacturing to support clinical
Producing dry powders with the optimum aerodynamic particle
size distribution of 1-5 µm for pulmonary delivery is fairly
straightforward on a laboratory scale spray dryer. Feedstocks of low solids
concentration are typical; processing rates are kept relatively low and high
atomisation gas pressures are employed in order to generate the very small
particles needed for high levels of deposition and uptake in the alveoli.
Challenges arise when larger quantities of material are
required and a scaled-up, commercially viable process is essential.
Particles in the 1-5 µm range are notoriously difficult to produce and
collect efficiently on larger pilot or commercial scale spray dryers. Size
distributions can often creep upwards, and product yields can plummet. This is
particularly bad news for high value APIs!
The Upperton approach is to optimise the spray drying process
for product yield, with particle size no longer the primary focus. The
feedstock concentration and processing rate can both be increased;
significantly reducing both manufacturing time and cost. The spray dried
particles are then reduced to the target particle size distribution, using a
carefully controlled dry powder milling process. The result is a much faster,
more efficient process producing large quantities of powders with excellent
Impaction testing of our model pulmonary formulations shows that we can
reproducibly generate dry powders with an aerodynamic particle size
distribution of 1-5 µm, with fine particle fraction in excess of 70% when
formulated powders are delivered from commercially available DPI’s.
There is growing interest in the use of spray drying to
create biotherapeutic dry powder formulations. Spray drying is becoming
increasingly viewed as a more cost-effective method for enhancing the stability of thermo-sensitive molecules (such as proteins, peptides, monoclonal
antibodies and vaccines).
A key aspect in the successful development of dry powder formulations is
identifying suitable analytical techniques to evaluate the biologic in
question. These tests will be needed to: aid formulation development, determine the impact of different spray drying parameters on the product and to determine stability profile. There are a wide range of assays available so it is important to choose suitable assays that can provide insight into two important aspects of the final powders produced, namely assays that show:
- The biologic in question retains its structure and activity both during the spray drying process and on subsequent storage.
- The spray drying process is generating powders with the necessary physical properties required for powder handling, reconstitution and storage stability.
There is a range of potential assays that can be used
to evaluate the spray dried formulation, the list is extensive therefore,some of the key tests that practitioners might want to consider have been highlighted. The assays have been divided into two groups: those used to evaluate the physical properties of the spray dried powders and those assays designed to evaluate the structure, function and chemical properties of the biologic itself.
Physical properties of the spray dried powder
Particle size analysis
(Laser light scattering, impaction by ACI/NGI)
sizing will give an insight into powder handling requirements, storage
stability and performance in delivery devices such as dry powder inhalers.
(loss on drying,
Tight control of residual moisture is an important read out in the optimisation of spray drying conditions and tight specification will be needed in order to meet storage stability targets.
Thermal properties, such as moisture uptake, melting points or glass transition temperatures of the powders produced will impact on handling and storage stability.
Powder flow properties
(Bulk/tapped density, angle of repose)
One of the major challenges of spray drying is engineering powders that have suitable handling and flow characteristics.
for evaluating particle morphology, evidence of any crystallinity and
retention of physical structure of biologic (e.g. virosomes).
Structure, function and chemical properties of the biologic
analysis (size exclusion, reverse phase)
Established technique for evaluating aggregation of biologic molecules (during spray drying and on storage) and for evaluating chemical modification(s) of specific amino acids.
(denaturing/non-denaturing, Western blotting)
for evaluating covalent and non-covalent molecular weight changes of
structural components (including aggregation, dissociation and scission).
Biologic functional assays
activity, antigenicity, ELISA)
the activity of the molecule being formulated is an important test of the
molecule's integrity during spray drying and on subsequent storage.
technique especially useful for detecting oxidation and deamidation of amino
acid side chains that can occur during spray drying and on storage.
reconstitution time, presence of insoluble material (aggregation), substrate
to determine protein folding, looking at secondary and tertiary structures.
Spray Drying Biotherapeutics
Dry powder formulations of Biotherapeutics eliminate the
need for expensive cold chain storage and facilitate supply chain management.
Lyophilisation is traditionally used for the drying process, but in recent
years the semi-continuous, robust and scalable qualities of spray drying have
made it the drying process of choice.
With expert formulation and process development, even the most delicate
biomolecule can be spray dried with little or no loss of activity.
To understand this, it is useful to consider the spray drying process: The
solution is first pumped into the drying chamber through a two-fluid nozzle, at
the tip of which it is atomised into droplets by a flow of compressed air. The
design of the nozzle means that the cool atomisation air protects the liquid
from the high temperature of the drying gas right up until the point of
atomisation. Once the solution is atomised, the droplets dry very quickly in
the heated drying airstream; again, the biomolecule is protected from the heat
by an evaporative-cooling effect as the droplets dry. Once in the dry form,
biomolecules are generally much more robust than in solution, and the total
residence time within the spray dryer is only a matter of seconds, depending
upon the size of the dryer.
Biotherapeutic Formulation Development
Formulation development is important to ensure the stability
of biomolecules at three critical points during and after processing: on
solution atomisation, during the drying process, and on storage after drying.
Surfactants, such as polysorbates or poloxamers, offer protection at the
liquid-air interface during the atomisation stage, preventing protein
aggregation or denaturation.
Stabilisation during the drying process is achieved by the use of excipients
that can form hydrogen-bonds with the biomolecule. Sugars such as trehalose, raffinose, or dextran are commonly used, due to their high glass transition temperatures; offering enhanced
storage stability of the bioformulations. Combinations of amino acids such as
histidine, glycine, proline and arginine, can be tailored to offer effective
stabilisation; resulting in dry powder bioformulations with excellent stability
Polymers, for example: cyclodextrin, PVP, methyl-cellulose and eudragits may be used in bioformulations, both for enhanced
stability and for other purposes (controlled release, taste masking and enteric
Other commonly used excipients include:
Salts for increasing ionic strength of solution,
minimising electrostatic interactions, and control of pH
Divalent metal ions, such as zinc, to form
dimers and reduce protein aggregation
Amino acids, such as Leucine, and surfactants
such as Phophatidylcholine, for improved powder flow and aerosolization
Mucoadhesives such as chitosan in formulations for nasal delivery
Spray drying processing parameters can have a profound
effect on the properties of dry powder bioformulations, and the process development
phase is of critical importance.
In optimising the drying temperature, a balance must often be struck between
the need for a low residual moisture level in the product for optimum storage
stability, and a drying temperature that the biomolecule can withstand. The
drying temperature can also affect the stickiness of the product, depending
upon the glass transition temperature of the formulation.
Particle size and morphology have an impact on powder flow and aerosolisation properties, which are especially important
in formulations for inhaled or nasal delivery. These can be controlled by
optimisation of a range of process parameters: Feed solution concentration,
liquid feed rate, atomisation air pressure and air flow rate,
have the biggest impact on particle size. Drying air flow rate and temperature
affect the rate of drying and so can be used to change the morphology of the
Characterisation of Spray Dried Bioformulations
Upperton has a wide range of analytical techniques that can
be used to investigate the chemical and physical properties of dry powder
bioformulations. These include HPLC, gel electrophoresis, activity assays,
particle size analysis by laser diffraction and impaction (ACI/NGI), residual
moisture determination, differential scanning calorimetry, dynamic vapour
sorption, powder flow measurements, and scanning electron microscopy.
Upperton Pharma Solutions now has a fully commissioned
60 square metre non-GMP pilot plant, mirroring our GMP manufacturing facility.
The pilot plant is equipped for three scales of spray drying:
• ProCept 4M8-Trix for batch sizes of up to 300g
Intermediate Spray Dryer for batch sizes of up to 1kg
Niro Mobile Minor for batch sizes of up to 3kg
In addition, the pilot plant has all of the powder
handling and processing capabilities offered in our GMP manufacturing facility,
for downstream processing of spray dried powders into final dosage forms.
Formulations and processes optimised in our R&D
laboratories can be quickly scaled up to produce non-GMP material for
toxicology and stability studies and CMC batches. The mirroring of our GMP
capability enables a rapid seamless transfer of processes into clinical
manufacture, along with all of the expertise and formulation-specific know-how
built up during the development stages.
In 2014, Upperton Pharma Solutions was awarded a
prestigious Horizon 2020 grant as part of a European consortium led by Mymetics, a pioneering company at the forefront of the development
of virosome-based vaccines.
The MACIVIVA goal was to develop dry powder, thermostable, cold-chain
independent virosomal vaccine formulations for non-invasive needle-free
administration. Such solid form vaccines should reduce the cost and improve safety
and compliance in National Immunisation Programs, particularly in the developing
The Upperton formulation development team successfully developed spray dried
formulations of HIV virosomal vaccines for both oral and nasal delivery routes.
The optimised processes were scaled up and transferred into the company’s GMP
clean room facility, where batches of both the Oral and the Nasal formulation
Upperton’s spray dried Virosomal Vaccine
- Retained virosome structure and
particle size on spray drying
- Preserved antigenicity in the
final solid vaccine forms
- Retained the initial vaccine
immunogenicity after storage for three months at 40°C / 75%RH
- Both nasal and oral formulations
were successfully dosed in animal models
- The immunogenicity of the nasal
solid vaccine form was comparable to subcutaneous injection of the
reference liquid vaccine
Participation in the MACIVIVA
project has enabled Upperton to expand their technical capabilities to include
GMP manufacture of solid form virosomal vaccines.
Successful Completion of N2 Business Growth Grant
In October 2017, Upperton was delighted to be awarded grant
funding by the Nottinghamshire-based N2 Business Growth Fund to support
investment into a capital project leading to business growth and the creation
of new sustainable jobs. Upperton used the funds to support the establishment
of a GMP clinical manufacturing capability at its Nottingham site.
The success of the project was easily measured:
In November 2018 Upperton Pharma Solutions’ manufacturing facilities passed
inspection by the UK Medicines and Healthcare products Regulatory Agency. The
MHRA licence allows the company to develop pharmaceutical formulations for
oral, nasal and pulmonary delivery right through from early feasibility studies
to scale up and Phase I & II clinical manufacture, all from its Nottingham
Science and Technology Park site.
Upperton Pharma Solutions’ new pharmaceutical spray drying manufacturing facilities at Nottingham Science and Technology Park have successfully passed inspection by the UK
Medicines and Healthcare products Regulatory Agency (MHRA).
A pharmaceutical spray drying contract development and manufacturing organisation (CDMO),
Upperton Pharma Solutions moved to its new facilities on Nottingham Science and Technology Park from its previous headquarters at BioCity Nottingham in March 2018, as part of a planned expansion of its services.
The company has invested heavily in the new facilities both in terms of building enhancements and in the expansion of its processing and analytical
The successful MHRA inspection provides Upperton Pharma Solutions with the
necessary MHRA licenses for manufacture, downstream processing into capsules
and tablets, as well as release of spray dried formulations of Biotherapeutics and small molecule APIs for clinical trials.
The company is now able to develop pharmaceutical formulations for oral, nasal and pulmonary delivery from early feasibility studies to Phase I & II clinical manufacture, from its Nottingham Science and Technology Park site.
Richard Johnson, CEO and Founder of Upperton Pharma Solutions, said: “We are absolutely delighted with the expansion of our capabilities in GMP clinical manufacturing and look forward to seeing our clients’ projects progress within Upperton, from early formulation development studies right through to clinical manufacture.”
“The positive endorsement by the MHRA will enable a seamless transition from R&D to GMP manufacture within the organisation, ensuring that all of the
project-specific knowledge and expertise developed in R&D will flow through to the GMP manufacturing processes.”
Paul Kelsall, Director of Clinical Trials Manufacturing commented: “This is a great opportunity for our business and is a result of our team’s commitment to
achieve the targets and aspirations of our business. We are looking forward to working with our clients and offering services from early stage development
through to clinical manufacture. These are exciting times for Upperton as we
continue to move forward and expand our capabilities.”
To learn more visit our GMP page
Upperton Pharma Solutions: At a time when the global CDMO market place is consolidating, Upperton Pharma Solutions remains as one of the few independent CDMO service providers with a specific focus on developing pharmaceutical
dosage forms using its specialised spray drying capabilities. Upperton provides a range of integrated services to the pharmaceutical and biotech sectors around the world. The services include: early feasibility studies, formulation
development for both small molecule APIs and Biotherapeutics for a range of
final dosage forms and GMP manufacture of materials for Phase I & II
clinical trials. Full analytical support, including ICH stability studies,
The company is a privately-owned
organisation that has grown organically over almost 20 years and now employs 24 highly skilled personnel. Upperton Pharma Solutions has its headquarters in
Business Development Associate
Upperton Pharma Solutions, Albert Einstein Centre, Nottingham Science & Technology Park
Nottingham NG7 2TN
T: +44 (0) 115 855 7050 (Monday to Friday 8.30am – 4.30pm)
Upperton Pharma Solutions will be exhibiting at AAPS
PharmSci360 for the first time, with this year’s event running from November
5th – 7th in Washington, D.C.
CEO & Founder Dr Richard Johnson and
Business Development Executive Annette Kleiser
be available at booth 1643 to discuss how Upperton can support your development
programme from early feasibility to clinical trials manufacturing
Richard will also be presenting a scientific
poster titled “Developing Cold Chain Independent Vaccines - Spray-drying of
Virosomes to Produce Dry Powder Formulations”, on Tuesday
This presentation will be based on the work of
the MACIVIVA project which has the end goal of producing pioneering virosome-based vaccines against life threatening dise
Find Richard at Booth 1643 or arrange a meeting by contacting us.
extending our capabilities Upperton’s family have grown from three members
of staff four
ago, to twenty-one staff this year. The latest staff updates are:
Kelsall, Director of Clinical Trials Manufacturing
experience in both sterile and non-sterile manufacturing, formulation
development and facilities management. Paul formerly worked for Boots, Reckitt Benkiser, Nova Laboratories and Aesica.
Bayliss, Director of Quality & Compliance
implementing, maintaining and remediating quality management systems. Sarah
joins us from Aesica.
Williams, Head of Clinical Manufacturing
developing and manufacturing investigational medicinal products for Phase I
II clinical trials. Thomas joins us from Quotient Sciences.
Gray, Senior QC Analyst
QC testing, early formulation development analysis and analytical method
qualification. Rebecca joins us from Quotient Sciences.=
Fisken, Business Development Associate
Klara joins us
from the University of Nottingham, where she has just completed an MSc in
Biopharmaceutical Biotechnology and Entrepreneurship.
Rose, Junior Project Scientist
Ella joins us
from Nottingham Trent University as a year long placement student, where she is
currently studying towards a BSc in Chemistry.